MOSCOW, may 6 — RIA Novosti. A study conducted by American scientists showed that treatment of severe patients with COVID-19 anticoagulants to slow blood clotting, increases the chances of survival. The results were published in the journal of the American College of Cardiology.
a large number of patients hospitalized with a diagnosis of COVID-19, to develop life-threatening complications associated with a high level of thrombosis. medical Scientists from the Medical school at the hospital mount Sinai to new York, compared the survival rates and duration of treatment among patients treated with and not treated during hospitalization intravenous thrombolytics.
“As a cardiologist for three weeks I have seen an increase in the number of blood clots in hospitalized patients with COVID-19. It is therefore very important to find out whether anticoagulation benefits in the treatment” — presented in press release medical schools in the words of one of the authors of the study, doctor of medical Sciences, Anu Lala (Lala Anu).
the study involved 2773 confirmed COVID-19-positive patients admitted to five hospitals network mount Sinai for the period from 14 March to 11 April 2020.
“Our study shows that the anticoagulant medication that is taken orally, subcutaneously or intravenously, can play a major role in the treatment of patients with COVID-19, and it can prevent the possibility of fatal events associated with the coronavirus, including heart attack, stroke and pulmonary embolism, says study leader Valentin Fuster (Fuster Valentin), chief doctor of the hospital mount Sinai. — the Use of anticoagulants must always provide for patients with COVID-19, however, each case should be evaluated individually, taking into account the potential risk of bleeding.”
From the analyzed patients, 28 percent — 786 — received full dose anticoagulation, a higher than normally prescribed for the prevention of blood clots or those who have already revealed the blood clots.
Of the patients who survived, those who took anticoagulants, died after spending an average of 21 a day in the hospital, compared with patients not taking anticoagulants, who died after an average of 14 days in the hospital.
Of intubated patients who survived, those who did not take anticoagulants died within 9 days, and those who took — 21 days.
“We hope that this report about the relationship of anticoagulant therapy with improved survival is confirmed in future studies. Scientists clinics mount Sinai continue to analyze data to contribute to efforts to find effective treatments COVID-19”, — said one of the authors of the article, Dr. copper��ins David Reich (David Reich), President and chief operating officer of the hospital mount Sinai.
